NuBalance Health

NuBalance Health operates as a telehealth-focused hormone optimization and peptide therapy clinic serving patients in Ohio and Georgia. Founded on the principle that hormone imbalances underlie many age-related health concerns, the clinic provides remote consultations and treatment coordination for adults seeking alternatives to conventional symptom management. The Dublin, Ohio-based practice has built a patient base across two states through virtual care delivery, eliminating geographic barriers for individuals in both urban and rural communities who lack local access to specialized hormone and peptide services.

The clinic's peptide therapy program centers on Sermorelin, a growth hormone-releasing hormone (GHRH) analog consisting of the first 29 amino acids of naturally occurring GHRH. Unlike synthetic human growth hormone, Sermorelin stimulates the pituitary gland's own production of growth hormone, working within the body's feedback mechanisms. NuBalance Health prescribes Sermorelin primarily for patients experiencing symptoms associated with age-related growth hormone decline, including decreased muscle mass, increased body fat composition, reduced exercise capacity, and diminished recovery from physical stress. The treatment protocol typically involves subcutaneous self-administration, with dosing individualized based on initial hormone panels, body composition metrics, and patient-reported outcomes tracked through follow-up assessments.

NuBalance Health's telehealth model requires patients to complete comprehensive intake forms detailing medical history, current medications, and specific health objectives before their initial video consultation. Providers review lab work ordered through partnered facilities in the patient's home state—Ohio or Georgia—analyzing hormone levels including IGF-1, thyroid function, sex hormones, and metabolic markers. During virtual appointments, clinicians discuss lab findings, explain how Sermorelin functions differently from direct hormone replacement, and outline realistic expectations regarding timeline and results. The clinic ships prescribed medications directly to patients' homes through licensed compounding pharmacies, accompanied by detailed administration instructions and injection supplies. Follow-up consultations occur at scheduled intervals to assess progress, adjust dosing if needed, and order repeat labs to monitor IGF-1 response and safety parameters.

Patients beginning Sermorelin therapy at NuBalance Health typically start with conservative dosing, gradually titrating upward based on tolerance and response. The clinic educates patients that Sermorelin effects accumulate over weeks to months rather than days, with initial changes often including improved sleep quality and recovery, followed by gradual shifts in body composition and energy levels. Providers emphasize that peptide therapy works synergistically with lifestyle factors—adequate protein intake, resistance training, and sleep hygiene—rather than serving as monotherapy. The telehealth format includes secure messaging for questions between appointments, allowing patients to report side effects or concerns without waiting for scheduled visits. This accessibility has contributed to the clinic's 5.0-star rating across 20 Google reviews, with patients noting responsiveness and thoroughness in addressing individual concerns.

NuBalance Health's restriction to Ohio and Georgia reflects state-specific telehealth regulations and medical licensing requirements rather than clinical limitations. The Dublin location serves as the administrative hub, though patients never visit a physical office. This virtual-first approach reduces overhead costs compared to brick-and-mortar practices, potentially translating to more accessible pricing for patients paying out-of-pocket, as many peptide therapies fall outside insurance coverage. The clinic's focus on Sermorelin as its primary peptide offering allows for specialized expertise in this particular compound, including recognition of contraindications such as active malignancy, and appropriate patient selection based on pituitary function and overall health status.